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Abstract
Background: The main genomic region controlling the predisposition to type 1 diabetes is the
Human Leukocyte Antigens (HLA) class II of the major histocompatibility complex. Association
with different HLA types depends also on the studied populations. In our investigation, we tried to
measure the phenotypic HLA class II association frequencies of DR3 and/or DR4 antigens, using a
serologic method called microlymphocytotoxicity analysis, in diabetic and nondiabetic (ND)
subjects originating from the west-Algerian region of Tlemcen. The aim of the present study was
to determine which HLA DR antigens represent a high susceptibility to develop the disease in this
area. Using a case-control retrospective study design, we randomly recruited ninety-one related
subjects, 39 type 1 diabetics and 52 ND as controls, at the Internal Medicine Board of Medical
Centre University of Tlemcen.
Results: DR3 antigen frequencies were comparable between the type 1 diabetics and the ND
subjects and showed no association with the disease (p = 1.000, OR = 0.95), whereas DR4 and
DR3DR4 antigens were associated with susceptibility to develop type 1 diabetes (DR4; OR = 2.10,
DR3DR4; OR = 1.30). Also, no incidence for DR3 (p = 0.2646) or DR3DR4 (p = 0.0699) antigen
frequencies was related to the sex ratio. However, significant differences in HLA DR4 frequencies
between type 1 diabetics and ND were found to be related to sex (p = 0.0085).
Conclusion: Taken together, our investigation showed that the strongest association with type 1
diabetes was noticed in the presence of HLA DR4 antigens followed by DR3DR4 antigens. This
study highlighted a characteristic of Tlemcen population; a history of consanguineous marriages.
Association studies between the disease and genetic polymorphisms should be undertaken in a
population where consanguinity is more limited to reduce confounding in result interpretations.
Background
The type 1 diabetes, previously called insulin-dependent
diabetes mellitus (IDDM), is the consequence of progres-
sive and selective destruction of pancreatic β cells by an
immune-mediated process [1], resulting in an absolute
lack of insulin [2]. It is well established that this self-
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destruction is primarily provoked by the activation of the
autoreactive T lymphocytes by the production of T-helper
1 cytokines [3,4]. In addition, the difference of the epide-
miological data from one region to another could largely
explain why the release of the autoimmunity is stimulated
under the influence of one or more environmental factors
[5,6], in genetically predisposed subjects. It is currently
obvious that the strongest genetic susceptibility of predis-
position is allotted to the IDDM1 alleles located in the
HLA locus of the chromosome 6p21 [7-9], and the non-
HLA alleles, particularly the IDDM2 polymorph gene
located in the region 5' of the insulin gene (INS) promoter
situated on the chromosome 11p15 [10,11]. Other
regions of the genome were identified as IDDM3, coding
for the IGF1 receptor, IDDM4, located near the fibroblast
growth factor 3 gene, IDDM5, near the estrogens receptor
gene [7] etc. The majority of these regions have no possi-
ble statistical criteria allowing them to be clearly linked to
the disease [11]. In all cases, it is mainly HLA alleles that
present a high risk of contracting the disease compared to
non-HLA alleles [6,12]. Due to this, they are qualified as
high genetic predictive markers of developing type 1 dia-
betes in families having a type 1 diabetic member. Inter-
estingly, the disease prediction offered with success the
possibility of clinical trials to delay, or even prevent the
appearance of type 1 diabetes.
However, the different HLA types associated with diabetes
depend also on the population. The purpose of our study
is to measure HLA DR3 and/or DR4 antigen frequencies
and their association in diabetic and nondiabetic subjects
originating from the west-Algerian region of Tlemcen.
Using a case-control retrospective study design, we
attempt to determine which is the greatest HLA DR sus-
ceptibility contributing to developing type 1 diabetes.
Ninety-one (91) eligible subjects (thirty-nine (39) type 1
diabetics and fifty-two (52) nondiabetics with relatives
with type 1 diabetes as controls), were recruited at the
Internal Medicine Board of the Medical Centre University
of Tlemcen.
Results
Table 1 summarizes HLA DR3, DR4 and DR3DR4 antigen
frequencies in type 1 diabetics and their nondiabetic rela-
tives.
DR4 and DR3DR4 antigens showed an association with
susceptibility to type 1 diabetes (DR4; OR = 2.10,
DR3DR4; OR = 1.30, that is respectively OR confidence
interval 1.04–4.24 and 0.60–2.80, 95% CI), in contrast,
DR3 antigens showed no association with the disease (OR
= 0.95, OR confidence interval 0.48–1.87, 95% CI). It is
important to notice that the strongest association is found
in DR4 phenotype as indicated in Figure 1.
In addition, the phenotypic frequency of DR4 or DR3DR4
molecules is higher in diabetic group than in the control
one, although the difference did not reach significance
level in DR3DR4 frequencies (p = 0.0361 and p = 0.5887
respectively). On the contrary, the DR3 molecules fre-
quency is slightly decreased in type 1 diabetic patients
compared to the controls and presents no statistically sig-
nificant difference (p = 1.000). Furthermore, no incidence
was related to the sex criteria for the frequencies of DR3
and DR3DR4 molecules (p > 0.05). However, significant
differences in HLA DR4 frequencies are linked to the
female sex and present a value definitely higher in type 1
diabetic patients compared to those of nondiabetics for
the same sex (p < 0.05) (Figure 2).
Table 1: HLA DR phenotypic frequencies according to p-values and Odds ratio in type 1 diabetic and nondiabetic subjects.
Type 1 diabetics n = 39: 15 M/24 F Nondiabetic controls n = 52: 21 M/31F
Frequency (Proportion and %)
HLA M F M F p Odds ratio (95 % CI)
DR3 3 (7.69) 7 (17.9) 5 (9.62) 9 (17.31) 0.2646a 0.95 (0.48–1.87)
10 (25.64) 14 (26.92) 1.000
DR4 4 (10.26) 9 (23.08) 6 (11.54) 4 (7.69) 0.0085 a, * 2.10 (1.04–4.24)
13 (33.33) 10 (19.23) 0.0361*
DR3DR4 4 (10.26) 4 (10.26) 2 (3.85) 7 (13.46) 0.0699a 1.30 (0.60–2.80)
8 (20.51) 9 (17.31) 0.5887
DR3 and/or DR4 11 (28.21) 20 (51.28) 13 (25.0) 20 (38.46) 0.5791a 2.21 (1.13–4.36)
31 (79.49) 33 (63.46) 0.0194*
X/X 4 (10.26) 4 (10.26) 8 (15.38) 11 (21.15) 0.0111 a, *-
8 (20.51) 19 (36.54) 0.0194*
ap-Values related to the sex ratio comparison (male = M, female = F). * p < 0.05. X = non-DR3, non-DR4.BMC Genetics 2004, 5:24 http://www.biomedcentral.com/1471-2156/5/24
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HLA DR antigen associations with type 1 diabetes Figure 1
HLA DR antigen associations with type 1 diabetes. The block boxes represent the odds ratios (OR). The horizontal 
lines represent the lower and upper confidence limit of OR (confidence interval, 95 % CI).
HLA DR antigen frequencies compared to the sex ratio Figure 2
HLA DR antigen frequencies compared to the sex ratio. * p < 0.05, Type 1 diabetics vs. control subjects.
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Discussion
Type 1 diabetes is a polygenic disease which results from
the interaction between environmental (viral, toxic, nutri-
tional, socioeconomic [6]) and genetic factors. It is the
form of diabetes which occurs mainly in children and
young adults [13].
Fortunately, molecular epidemiology offers the hope of
the possibility of preventing the disease in the future, by
evaluating the potential factors of risk of developing this
pathology [6]. Although almost 90 % of new cases of type
1 diabetes occur sporadically, studies of individuals with
a diabetic relative in their family are essential [4].
It is well established that associations between type 1 dia-
betes and certain HLA antigens largely facilitate the iden-
tification of the subjects having a potential risk to develop
the disease. Among the putative HLA molecules known to
confer a high susceptibility are DQA1 (*0301)-DQB1
(*0302) (= DQ8), DQA1 (*0501)-DQB1 (*0201) (=
DQ2), DRA-DRB1 (*0401) (= DR4) and DRA-DRB1
(*0301) (= DR3) [14]. However, epidemiological studies
showed that the different HLA types associated with the
diabetes depend also on the various populations. For
instance, the risk of developing type 1 diabetes in Cauca-
sians is greater if they are carrying the HLA A8 and B15,
while DQ6 alleles are protectors [11,14,15]. Among Japa-
nese, it is the association with the HLA B54 that confers a
higher susceptibility to develop the disease, while the
strongest association was found with HLA DR and HLA
DQ locus [11].
In Algeria, and especially in its western region (Tlemcen),
which is known for its history of consanguineous mar-
riage, there is a high rate of consanguinity. This fact could
increase the risk of developing type 1 diabetes by favour-
ing the transmission of HLA haplotypes and recessive
genes of susceptibility except for HLA antigens that are
common in both parents. For these reasons, we were
interested in checking whether phenotypically DR3DR4
antigens would involve less risk to develop the disease, in
comparison with DR3 or DR4 antigens, knowing the fact
that the presence of a probable consanguinity could
reduce the frequency of DR3DR4 polymorph phenotype
compared to that of DR3 or DR4 phenotype.
On a purely comparative basis, similarities seem to be
found between our results and those of other investigators
[5,13,15] with regards to HLA DR4 or DR3DR4 frequen-
cies, which are higher in the type 1 diabetic than the
nondiabetic population. On the contrary, the HLA DR3
antigens showed comparable frequencies in both groups
of our sample. Consequently, these observations associat-
ing DR3 phenotype to a protector effect against type 1 dia-
betes in our studied population are thus do not conform
with those reported in the literature [15-18]. However,
DR4 and DR3DR4 antigens are obviously associated with
susceptibility of developing the disease. It should also be
noted that DR3DR4 antigens might represent a weaker
predictive value of disease risk. We concluded from this
that the non-excess of DR3DR4 antigens, or comparable
frequencies of DR3 molecules between type 1 diabetic
patients and ND relative controls, might be a strong indi-
ces of consanguinity in our sample. A recent study carried
out in Sweden showed that HLA DR3 is associated to the
development of type 1 diabetes and the incompatibility of
blood group ABo [19]. One can thus note that the role of
the HLA DR3 antigens in conferring risk for type 1 diabe-
tes can be masked in the homogeneous populations. Due
to the restricted size of our sample, which may influence
our interpretation, we should not consider the odds ratio
of HLA DR3 antigens or the eventual consanguinity of our
studied population. Moreover, many evidences [20-23]
incriminate DR3 and/or DR4 antigens in the susceptibility
to type 1 diabetes and their association with the detected
autoantibodies in this disease. Indeed, the marks of
autoimmunity are much more observed in the diabetic
patients carrying DR3 or DR4 antigens than in the diabetic
patients where DR3 or DR4 antigens were absents [13].
Furthermore, recent research indicates that a subject with
HLA DR4 or DR3 alleles has three or four times more
chance of developing type 1 diabetes compared to the
general population; DR3DR4 is associated with the high-
est risk (20 to 40 times more) [11].
In Algeria, very few investigations have been undertaken
to study the impact of the genetic background on the risk
to develop type 1 diabetes in its population, where an
annual average incidence of 4.7 per 100000 has already
been listed [24]. In a similar study carried out on Algerian
unrelated type 1 diabetics (n = 50) and nondiabetics con-
trols (n = 46), the presence of DR3-DQ2 (linkage disequi-
librium) in 45 % of patients and in 13 % of controls was
detected by molecular genotyping method using PCR
(polymerase chain reaction) and SSO (sequence specific
oligonucleotide). DR4-DQ8 was found in 37 % of dia-
betic cases and in 4 % of control groups [25]. Finally, asso-
ciation with type 1 diabetes attributed to DR-B1*0405
(alleles of DR4 antigens expression) susceptibility showed
a match with our results; however, the DR4 antigens were
found to be linked to the female sex. According to the
results showed in Table 1, there is no difference between
men and women patients with type 1 diabetes carrying
DR4 antigens, but a significant difference was noticed in
female sex, either women were contracted or not with dia-
betic disease.
It is certain that screening of HLA class II sub-types and
determination of DNA coding sequences allows more pre-
cise characterization of ethnic groups, especially, becauseBMC Genetics 2004, 5:24 http://www.biomedcentral.com/1471-2156/5/24
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the same coded molecules can differ by the position of
few amino acids. For example, it is well established that
DQA1 and DQB1 alleles (sub-types of HLA DQ) code
respectively for the alpha and beta chain of the DQ mole-
cule [6]. Thus, the combination of DQ alpha with Arg in
position 52 (Arg-52) and DQ beta in position 57 without
Asp (non-Asp 57) is called a diabetogenic heterodimer
which is the biggest risk factor of type 1 diabetes in Cau-
casian. Nevertheless, among the Japanese population,
type 1 diabetes is particularly associated with HLA DQ
alpha Arg-52, but not with HLA DQ beta non-Asp 57 [5].
Moreover, it is true that the search of an association with
a candidate gene allows a better characterization for most
of the frequent multifactorial diseases, because the candi-
date genes are directly implied in the pathological proc-
esses. Today, it is reported that the CTLA-4 (cytotoxic T-
lymphocyte antigen-4) allele, localised on the chromo-
some 2p33, former IDDM12, is largely associated with the
susceptibility of numerous common complex diseases,
such as the common autoimmune disorders Graves' dis-
ease, the autoimmune hypothyroidism and type 1 diabe-
tes [26]. Combined, these pertinent observations still
open new perspectives for debating this crucial subject
concerning the public health.
Conclusion
Type 1 diabetes, or youth diabetes, is a multifactorial dis-
ease occurring on a genetic ground of predisposition and
starts under certain environmental conditions. The most
effective preventive strategy must be designed at the pre-
diabetes stage, since immune and/or genetic markers can
easily indicate subjects with high risk before the clinical
symptoms. Thus, the genetic analysis of HLA class II asso-
ciations has allowed a screening of the contributing mol-
ecules to the type 1 diabetes development and the
selection of subjects, which are likely to contract the
disease.
In this study, we were confronted with difficulties in inter-
pretation of our results which are mainly due to the pres-
ence of some indices of consanguinity in our studied
population, showing a non excess of DR3DR4 phenotype
compared to the DR3 or DR4 phenotype, and a no link of
DR3 phenotype to the disease. This result could be due to
an ethnic characteristic of Tlemcen population, a history
of consanguineous marriages. Nevertheless, these prelim-
inary results made it possible to answer the asked ques-
tions. Thus, the strongest type 1 diabetes association is
statistically revealed with phenotypic expression of DR4
followed by DR3DR4 phenotype. Association studies
between the disease and genetic polymorphisms should
be carried out on the population having more limited
consanguinity to reduce confusions in result
interpretations.
Methods
Subjects
The study was conducted on ninety-one first-degree
related subjects (brothers, sisters and siblings), randomly
recruited at the Internal Medicine Board of the Medical
Centre University of Tlemcen (west-Algeria). The sample
included thirty-nine patients with type 1 diabetes (15
males, 24 females), and fifty-two healthy subjects (21
males, 31 females) selected from diabetes relatives as con-
trols. Prior medical histories and personal characteristics
were obtained from participants via a questionnaire. The
patients' mean (± Standard Deviation) age at clinical
onset was 12.28 ± 5.97 years with range of 5 to 22 years
and median of 11 years. Subjects who were not first degree
related and who were not originating from Tlemcen
region were excluded. The use of first-degree relatives
eliminates exposures of environmental factors such as
food items and viruses since first-degree relatives usually
share the same milieu. For execution of the protocol, the
informed consent was obtained from all the participating
subjects to the designated study.
HLA phenotyping (standard complement-dependent 
assay)
The applied serologic technique lies on the aptitude of the
antibodies to recognize allotropic determinants of HLA
molecules on cellular surface [27]. This method is sensi-
tized by a reaction of microlymphocytotoxicity [28,29],
which uses specific anti-HLA DR antisera and rabbit com-
plement of commercial typing tray (Biotest, Germany).
Initially, the peripheral blood lymphocytes (PBL) were
separated from the other illustrated elements of venous
blood (collected in EDTA-containing tubes) by density
gradient centrifugation on Ficoll-Hypaque [30]. B lym-
phocytes were isolated by using nylon-wool-separated
columns [31].
Statistical analysis
The comparison of phenotypic frequencies was obtained
by using chi-square analysis with Yates' correction or by
Fisher's Exact test, whenever appropriate. The application
of the observed χ2 vs. expected χ2 was employed to show
significance of frequency differences with the sex ratio. A
p value of less than 0.05 was considered statistically signif-
icant (two-by-two table: degrees of freedom (df) = 1, chi-
square ≥ 3.84) [32]. The association between HLA anti-
gens and type 1 diabetes was performed by determination
of odds ratio (OR) [33,34] (confidence interval, 95 % CI).
All statistical analyses were performed using the Epi Info
2000 Version 1.0 for Windows 95, 98, NT, and 2000 com-
puters (Epi Info, Atlanta, Georgia, USA) and STATISTICA
Version 5.0, '97 (STATISTICA, StatSoft, Paris, France).BMC Genetics 2004, 5:24 http://www.biomedcentral.com/1471-2156/5/24
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